"Will ENMD capitalize on PR of Mayo clinic results AND lead article in the journal Cancer Research? These developments will drive herds of potential investors who don't know squat about ENMD to the website. The news IMO should be front and center at www.entremed.com"
The news is pleasantly good, but not new or surprising to those who have been following the company for awhile. In particular IMO, this is encouraging but not something for the company to stand up and shout about since the study was about Panzem's source molecule used in a way not currently in trials and not the product it is currently in development (PanzemNCD oral formulation is here and now, but an injectable version would have to go back 20 spaces and wait until the next turn before rolling the dice). My concern about overstating this study is that people will over react, blame the company for the hype, and not consider our team credible when something infinitely more important shows up in the human trials real soon now.
"Panzem's first killer indication in cancer could be as an injectable breast ca anti-metastatic for osteolysis. Who woulda thunk it?"
While it will be great if one day Panzem is found to provide the benefits suggested by the Mayo/Oregon State study, Panzem's first rocking success will hopefully happen soon as orally delivered PanzemNCD as a combo therapy in the human trials. And, please don't use the word "killer" to mean something positive in the context of a cancer med. Avastin has actually done this to patients in trials, ya know, but our team will hopefully never have to deal with this problem!
Market Data 
Markets 
AI
